Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eytan Stein, Stéphane De Botton, Arnaud Pigneux, Christine McMahon, Brian Ball, Gautam Borthakur, Alireza Eghtedar, Suman Kambhampati, Jason Tache, Eunice S. Wang, Heather Kelley, Angela Volkert, Kristen Baker, Qing Kang-Fortner, Catherine Madigan, Erica D. Warlick, David A. Roth, Michael Kelly, Daniel Aaron Pollyea
Institutions: Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Centre Hospitalier Universitaire de Bordeaux, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Colorado Blood Cancer Institute, BRCR Global (United States), Roswell Park Comprehensive Cancer Center, Syros Pharmaceuticals (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286295251